pre-IPO PHARMA

COMPANY OVERVIEW

Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (formerly AMG 899, now TA-8995) a selective cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating obicetrapib as the preferred ApoB and LDL-c lowering therapy for patients with ASCVD/FH on the maximally tolerated dose of statin therapy. NewAmsterdam Pharma is headquartered in Naarden, The Netherlands.


LOCATION

  • Naarden, , The Netherlands

  • THERAPEUTIC AREAS

  • Cardiovascular Disease

  • WEBSITE

    https://www.newamsterdampharma.com/


    CAREER WEBSITE

    https://www.newamsterdampharma.com/careers-and-contact


    SOCIAL MEDIA


    INVESTORS

    ascendant-biocapital forbion morningside-ventures


    PRESS RELEASES


    Nov 15, 2022

    Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.


    Oct 5, 2022

    NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study Evaluating Obicetrapib in Japanese Patients


    Aug 29, 2022

    NewAmsterdam Pharma Showcases Leadership in Cardiometabolic Disease Treatment in Multiple Presentations at ESC Congress 2022


    Aug 11, 2022

    NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib


    Jul 28, 2022

    NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia


    For More Press Releases


    Google Analytics Alternative